Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel and XPartners in connection with the acquisition of Projektkompaniet
Mandate

Vinge advises Axcel and XPartners in connection with the acquisition of Projektkompaniet

May 15, 2024 Banking and Finance M&A Real Estate and Construction

Vinge has advised Axcel VII (“Axcel”) and XPartners Samhällsbyggnad (”XPartners”) in connection with the acquisition of Projektkompaniet i Motala AB (”Projektkomapniet”).

Projektkompaniet is a construction consultancy specialising in project and construction management, architectural design, commercial kitchen design and construction. The Company specialises in investment projects and offers services at all stages of the construction process, with the main segments being public and commercial projects.

Vinge’s team consisted of responsible partner Christina Kokko together with Carl Fredrik Wachtmeister, Gustav Persson and Alexander Rüdén (M&A), August Ahlin (banking and finance), Clara Klingspor (Construction) and Cecilia Loctander (Transaction Support Co-ordinator).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026